Migraine-Associated TRESK Mutations Increase Neuronal Excitability through Alternative Translation Initiation and Inhibition of TREK.
Autor: | Royal P; Université Côte d'Azur, CNRS, Inserm, Institut de Biologie Valrose, Nice, France; Laboratories of Excellence, Ion Channel Science and Therapeutics, Nice, France., Andres-Bilbe A; Neurophysiology Laboratory, Department of Biomedicine, Medical School, Institute of Neurosciences, Universitat de Barcelona, IDIBAPS, Barcelona, Spain., Ávalos Prado P; Université Côte d'Azur, CNRS, Inserm, Institut de Biologie Valrose, Nice, France; Laboratories of Excellence, Ion Channel Science and Therapeutics, Nice, France., Verkest C; Laboratories of Excellence, Ion Channel Science and Therapeutics, Nice, France; Université Côte d'Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France., Wdziekonski B; Université Côte d'Azur, CNRS, Inserm, Institut de Biologie Valrose, Nice, France; Laboratories of Excellence, Ion Channel Science and Therapeutics, Nice, France., Schaub S; Université Côte d'Azur, CNRS, Inserm, Institut de Biologie Valrose, Nice, France., Baron A; Laboratories of Excellence, Ion Channel Science and Therapeutics, Nice, France; Neurophysiology Laboratory, Department of Biomedicine, Medical School, Institute of Neurosciences, Universitat de Barcelona, IDIBAPS, Barcelona, Spain., Lesage F; Laboratories of Excellence, Ion Channel Science and Therapeutics, Nice, France; Université Côte d'Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France., Gasull X; Neurophysiology Laboratory, Department of Biomedicine, Medical School, Institute of Neurosciences, Universitat de Barcelona, IDIBAPS, Barcelona, Spain., Levitz J; Department of Biochemistry, Weill Cornell Medicine, New York, NY, USA., Sandoz G; Université Côte d'Azur, CNRS, Inserm, Institut de Biologie Valrose, Nice, France; Laboratories of Excellence, Ion Channel Science and Therapeutics, Nice, France. Electronic address: sandoz@unice.fr. |
---|---|
Jazyk: | angličtina |
Zdroj: | Neuron [Neuron] 2019 Jan 16; Vol. 101 (2), pp. 232-245.e6. Date of Electronic Publication: 2018 Dec 17. |
DOI: | 10.1016/j.neuron.2018.11.039 |
Abstrakt: | It is often unclear why some genetic mutations to a given gene contribute to neurological disorders and others do not. For instance, two mutations have previously been found to produce a dominant negative for TRESK, a two-pore-domain K+ channel implicated in migraine: TRESK-MT, a 2-bp frameshift mutation, and TRESK-C110R. Both mutants inhibit TRESK, but only TRESK-MT increases sensory neuron excitability and is linked to migraine. Here, we identify a new mechanism, termed frameshift mutation-induced alternative translation initiation (fsATI), that may explain why only TRESK-MT is associated with migraine. fsATI leads to the production of a second protein fragment, TRESK-MT2, which co-assembles with and inhibits TREK1 and TREK2, two other two-pore-domain K+ channels, to increase trigeminal sensory neuron excitability, leading to a migraine-like phenotype in rodents. These findings identify TREK1 and TREK2 as potential molecular targets in migraine and suggest that fsATI should be considered as a distinct class of mutations. (Copyright © 2018 Elsevier Inc. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |